Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of NWRD09 in HPV-16 Related Neoplasia and Cervical Cancer
NCT06741150Phase 1Recruiting
- Sponsor
- Newish Technology (Beijing) Co., Ltd.
- Start
- Jun 2024
- Primary completion
- Dec 2025
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of NWRD09 in cervical intraepithelial neoplasia (CIN), vaginal intraepithelial neoplasia (VAIN), vulvar intraepithelial neoplasia (VIN) and 1 more, sponsored by Newish Technology (Beijing) Co., Ltd. Primary endpoints: Safety at 21 days and Dose-limiting toxicity at 21 days. Started Jun 2024; status: recruiting.
02
Drugs
NWRD09
03
Conditions
cervical intraepithelial neoplasia (CIN)vaginal intraepithelial neoplasia (VAIN)vulvar intraepithelial neoplasia (VIN)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06741150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06741150.